• Twitter
  • Facebook
  • LinkedIn
  • English English English en
  • Português Português Portuguese (Brazil) pt-br
Murray Advogados
  • Home
  • The Firm
  • Areas
    • More…
      • Probate and Family Law
      • Capital Stock
      • Internet & Electronic Trade
      • Life Sciences
      • Capital and Financial Market Banking Law
      • Media e Entertainment
      • Mining
      • Intellectual Property
      • Telecommunications Law and Policy
      • Visas
    • Arbitration
    • Adminstrative Law
    • Environmental Law
    • Civil Law
    • Trade Law
    • Consumer Law
    • Sports Law
    • Market and Antitrust Law
    • Real Estate Law
    • International Law and Foreign Trade
    • Corporate Law
    • Labor Law
    • Tax Law
    • Power, Oil and Gas
  • Members
  • News
  • Links
  • Contact
    • Contact Us
    • Careers
  • Search
  • Menu Menu
Murray News

Cimed gears up to grow above market in 2022

Leader in sales volume of over-the-counter drugs expanded more than 20% in 2021

11/03/2022


Jose Roberto Lettiere — Foto: Silvia Zamboni/Valor

Jose Roberto Lettiere — Foto: Silvia Zamboni/Valor

Cimed, Brazil’s leader in OTC drugs in sales volume, grew twice as much as the country’s market for drugs last year and intends to repeat this performance in 2022. “There are still many open variables, but the plan is to grow stronger,” Chief Financial Officer José Roberto Lettiere said.

In 2021, while the Brazilian market grew 11%, according to data from the consultancy IQVIA, which audits retail pharmaceuticals, Cimed’s net revenue grew more than 20%.

According to Mr. Lettiere, heated demand for medicines and vitamins amid the Covid-19 pandemic and its sales mix allowed the pharmaceutical company to advance in revenue and return on capital employed, despite the challenges in the global supply chain, the impact of currency devaluation in costs and greater global competition for raw materials — the active pharmaceutical ingredients (APIs) used in the country are mostly imported, from China and India.

“We realized that Europe was starting to face logistical problems at the end of 2020 and we moved up the purchase of raw materials to avoid disruption,” the executive said. The challenges remained in 2021. But the vertical operating model, the focus on operating costs and agile management helped to protect the financial statement, he adds.

In the year, while the company’s net revenue grew 20.3% to R$1.58 billion, the cost of goods sold (COGS) advanced 27.6% to R$773.8 million. Recurring EBITDA rose 30.7% to R$403 million, with a margin of 25.5%, compared to 23.4% in 2020.

Net income for the year fell 15.1%, to R$242.8 million, pressured by the financial result and expenses related to the implementation of the new plant in Pouso Alegre (Minas Gerais) and the simplification of the company’s corporate structure. On the other hand, recurring net income rose 16.4% to R$255.1 million and ROCE increased five percentage points to 47.2%.

According to Mr. Lettiere, there are no IPO plans on the table right now. But Cimed could tap the capital market to finance an eventual more aggressive growth project. “Cimed wants to be the largest pharmaceutical company in Brazil. If it is necessary to go to the market for this, it will be studied,” the executive said.

At the beginning of the year, logistical challenges persist and the demand for medicines grew even faster, particularly anti-flu and anti-allergic drugs, given the advance of the omicron variant and the circulation of a new influenza virus, H3N2, in the country. But there were no problems in accessing raw materials to meet the demand, according to Mr. Lettieri.

Cimed has already obtained approval from health regulator Anvisa to transfer the production of medicines to the new factory in Pouso Alegre, in a process likely to be completed by the third quarter. With the unit, which has already received investments of R$300 million, Cimed doubles its solid production capacity, to 240 million units (boxes) per year.

In addition, R$300 million are set aside for the manufacturing complex over the next five years, increasing production capacity in other product lines.

Source: Valor International

https://valorinternational.globo.com
11 de March de 2022/by Gelcy Bueno
Tags: Cimed, pharmaceutical company in Brazil
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail

Pesquisa

Posts Recentes

  • Preventive Law.
  • Brazil confirms first avian flu case on poultry farm
  • Marfrig and BRF merger creates R$152bn global food powerhouse
  • Lula’s vetoes on offshore wind bill face backlash in Congress
  • Brazil’s ethanol seeks bigger role in energy transition

Arquivos

  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
© Copyright 2023 Murray Advogados – PLG International Lawyers - Support Webgui Design
  • Twitter
  • Facebook
  • LinkedIn
Agriculture minister to meet fertilizer exporters in Canadá High oil prices boost collection of states, municipalities
Scroll to top